Research Paper Volume 13, Issue 5 pp 6982—6998

Figure 4. Zeta55 inhibits tumor growth in a CRPC xenograft model. (A) Percentage change in individual tumor volume of NOD-SCID mice with subcutaneous tumor xenograft grown from VCaP cells. NOD-SCID mice were castrated when the tumor volumes reached about 250mm³ on 63 days after subcutaneous injection of VCaP cells. After 21 days when the xenografts continued to grow, the castrated mice were treated with daily oral Zeta55 (30 mg/kg or 60 mg/kg) or MDV3100 (30 mg/kg) for 49 days (n=6). Tumor sizes were monitored twice a week after treatment. (B) Mean tumor volumes (mm³, +SEM) of NOD-SCID mice after treatment. (C) Mean body weight (g, +SEM) of NOD-SCID mice after treatment. *, P < 0.01 vs. vehicle.